AAV Innovation Summit 2025

Optimizing genome integrity through AI and vector design

Raleigh-Durham, NC • March 201-5 PM

Join Form Bio and leading experts from industry and academia for a half-day summit on AAV innovation. This exclusive event will bring together top minds in gene therapy to explore the latest innovations, challenges and industry trends. Networking reception to follow.

Space is limited, register today.

Register Today

Speakers

Sebastian Aguirre Kozlouski

Sebastian Aguirre Kozlouski, PhD

Co-Founder & VP, Platform Development, Carbon Biosciences
Claire Aldridge, PhD

Claire Aldridge, PhD

Scientific Advisor & Former Chief Strategy Officer, Form Bio
Brooke Brown, PhD

Brooke Brown, PhD

Scientist, Analytical Development, BridgeBio
Adam Cockrell, PhD

Adam Cockrell, PhD

Sr. Director, Vector Biology, Solid Biosciences
Amicia Elliott, PhD

Amicia Elliott, PhD

Vice President, Product, Form Bio
Charles Feathers

Charles Feathers

Sr. Manager, Process Development, Tenaya Therapeutics
Michael Guerrero, PhD

Michael Guerrero, PhD

VP, Technical Development & Operations, BridgeBio
Paul Herzich

Paul Herzich

Chief Technology Officer, Solid Biosciences
Elizabeth Tseng

Elizabeth Tseng, PhD

Assoc. Dir. Product Marketing, Gene Therapy, PacBio
Fred Porter, PhD

Fred Porter, PhD

Chief Technical Officer, Taysha Gene Therapies
Anusha Sriraman, PhD

Anusha Sriraman, PhD

Program Manager, Life Sciences, Form Bio
Phillip Tai, PhD

Phillip Tai, PhD

Assistant Professor, UMass Medical School
Nam Tonthat, PhD

Nam Tonthat, PhD

Director, Analytical Sciences, AskBio
Robin Muthig

Robin Muthig

Sr. Director, Alliance for Regenerative Medicine
Beth Anne Childress

Beth Anne Childress, MS, PMP

VP, GMP Quality, AskBio
Jude Samulski, PhD

Jude Samulski, PhD

Alumni Distinguished Professor & Honorary Edward T. Samulski Professor of Medicine, Former Director of UNC Gene Therapy Center & Mentor to the Current Director

Preliminary Agenda

  • 12:30 PM
    Check-in & coffee
  • 1:00 PM
    Welcome Remarks
  • 1:10 PM
    Keynote: Advancing Gene Therapy from Discovery to Clinical Trials
    • Jude Samulski, PhD, Professor & Center Director at University NC, Chapel Hill
  • 1:40 PM
    Understanding AAV Vector Genome Heterogeneity
    • Phil Tai, PhD, Associate Professor, UMass Chan Medical
  • 2:05 PM
    Biophysical & Molecular Characterization of rAAV Species
    • Brooke Brown, PhD, Scientist, Analytical Development, BridgeBio
  • 2:25 PM
    Designing rAAV Vectors Using In Silico Vector Modeling
    • Adam Cockrell, PhD, Sr. Director, Vector Biology, Solid Biosciences
  • 2:45 PM
    Networking Break
  • 3:00 pm
    AI & In Silico Tools for Faster, More Predictable AAV Development
    • Amicia Elliott, PhD, Vice President, Product, Form Bio
  • 3:20 pm
    Challenges around Gene Therapy Manufacturing
    • Fred Porter, PhD, CTO, Taysha Gene Therapies
  • 3:40 pm
    AAV Working Group Panel: Standardizing & Reporting for Long-Read NGS & Analysis for rAAV Vectors
    • Moderator: Anusha Sriraman, PhD, Program Manager, Life Sciences, Form Bio
    • Brooke Brown, PhD, Scientist, Analytical Development, BridgeBio
    • Adam Cockrell, PhD, Sr. Director, Vector Biology, Solid Biosciences
    • Charles Feathers, Sr. Manager, Process Development, Tenaya Therapeutics
    • Nam Tonthat, PhD, Director Analytical Sciences, AskBio
    • Elizabeth Tseng, PhD, Assoc. Dir. Product Marketing, Gene Therapy, PacBio
  • 4:10 PM
    Gene Therapy State-of-the-Industry
    • Robin Muthig, Sr. Director, Membership, Alliance for Regenerative Medicine
  • 4:30 PM
    Executive Panel: From Innovation to Impact—Advancing Gene Therapy Development & Commercialization
    • Moderator: Claire Aldridge, PhD, Scientific Advisor & Former Chief Strategy Officer, Form Bio
    • Sebastian Aguirre Kozlouski, PhD, Co-Founder & VP, Platform Development, Carbon Biosciences
    • Michael Guerrero, PhD, VP Technical Development & Operations, BridgeBio
    • Paul Herzich, Chief Technology Officer, Solid Biosciences
    • Beth Anne Childress, MS, PMP - VP, GMP Quality, AskBio
    • Fred Porter, PhD, CTO, Taysha Gene Therapies
  • 5:00 PM
     Networking Reception

Areas of Focus

Utilizing long-read sequencing for AAV Genome Integrity Analysis

Advancing long-read sequencing analysis with open-source tools (bioRxiv publication)

Leveraging AI and in silico tools to accelerate AAV Gene Therapy Development

Who Should Attend?

Executives who work in AAV gene therapy sector

Scientists who work in AAV therapeutic development, including preclinical and manufacturing

blob image
Chemistry Texture 2

AAV Resource Hub

Explore best practices, tools and standards in AAV research and development
Visit the Hub
Black squares textured stacked